{"id":"W2892330548","doi":"10.1200/jco.2017.35.15_suppl.3057","title":"Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Université de Montréal; Hôpital Notre-Dame; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Atezolizumab; Adverse effect; Internal medicine; Melanoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy; Pembrolizumab; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001167877,0.000288574,0.0005499636,0.0004605468,0.0001280548,0.0005214431,0.00034555,0.0003227259,0.001870549],"category_scores_gemma":[0.0008099982,0.0001195389,0.0005116994,0.0004210737,0.0001107507,0.0003633016,0.0001976711,0.001013667,0.0005089515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005251442,"about_ca_system_score_gemma":0.0004424089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005422762,"about_ca_topic_score_gemma":0.002288357,"domain_scores_codex":[0.999732,0.00008631592,0.00004096178,0.00002979572,0.00008355175,0.00002737194],"domain_scores_gemma":[0.9995695,0.00009612433,0.0001892633,0.00002198608,0.00006803125,0.00005512271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02455592,0.001110366,0.01241282,0.002307651,0.00085537,0.0001869531,0.00005470793,0.001552226,0.01955664,0.000450856,0.01664976,0.9203066],"study_design_scores_gemma":[0.04397546,0.1644785,0.2473122,0.003187094,0.009706466,0.009612534,0.0002165193,0.01329028,0.04045629,0.002242238,0.465352,0.0001704521],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6086791,0.3569145,0.002638632,0.005361169,0.0007214402,0.000648271,0.004150351,0.0004343377,0.02045224],"genre_scores_gemma":[0.9202753,0.06486807,0.002587058,0.002745246,0.0005632516,0.000227133,0.005678092,0.00002876035,0.003027138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001870549,"threshold_uncertainty_score":0.006257594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1440716241624101,"score_gpt":0.5033347753420615,"score_spread":0.3592631511796514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}